The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition
Abstract
Improving T cell Ags by altering MHC anchor residues is a common strategy used to enhance peptide vaccines, but there has been little assessment of how such modifications affect TCR binding and T cell recognition. In this study, we use surface plasmon resonance and peptide–MHC tetramer binding at the cell surface to demonstrate that changes in primary peptide anchor residues can substantially and unpredictably alter TCR binding. We also demonstrate that the ability of TCRs to differentiate between natural and anchor-modified heteroclitic peptides distinguishes T cells that exhibit a strong preference for either type of Ag. Furthermore, we show that anchor-modified heteroclitic peptides prime T cells with different TCRs compared with those primed with natural Ag. Thus, vaccination with heteroclitic peptides may elicit T cells that exhibit suboptimal recognition of the intended natural Ag and, consequently, impaired functional attributes in vivo. Heteroclitic peptide-based immune interventions therefore require careful evaluation to ensure efficacy in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Research works printed but not linked: 58
- Davis, 1988, T-cell antigen receptor genes and T-cell recognition, Nature, 334, 395, 10.1038/334395a0 · DOI · Paper page
- Garcia, 1999, Emerging principles for T cell receptor recognition of antigen in cellular immunity, Rev. Immunogenet., 1, 75
- Chen, 2005, Structural and kinetic basis for heightened immunogenicity of T cell vaccines, J. Exp. Med., 201, 1243, 10.1084/jem.20042323 · DOI · Paper page
- Keogh, 2001, Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity, J. Immunol., 167, 787, 10.4049/jimmunol.167.2.787 · DOI
- Laugel, 2007, Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties, J. Biol. Chem., 282, 23799, 10.1074/jbc.M700976200 · DOI · Paper page
- Parkhurst, 1996, Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues, J. Immunol., 157, 2539, 10.4049/jimmunol.157.6.2539 · DOI · Paper page
- Shang, 2009, Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues, Eur. J. Immunol., 39, 2248, 10.1002/eji.200939338 · doi:10.1002/eji.200939338
- Terasawa, 2002, Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen, Clin. Cancer Res., 8, 41
- Valmori, 1998, Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol., 160, 1750, 10.4049/jimmunol.160.4.1750 · DOI · Paper page
- La Rosa, 2001, Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries, Blood, 97, 1776, 10.1182/blood.V97.6.1776 · doi:10.1182/blood.v97.6.1776
- Udaka, 1995, Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries, J. Exp. Med., 181, 2097, 10.1084/jem.181.6.2097 · doi:10.1084/jem.181.6.2097
- Rammensee, 1995, MHC ligands and peptide motifs: first listing, Immunogenetics, 41, 178, 10.1007/BF00172063 · DOI · Paper page
- Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics, 50, 213, 10.1007/s002510050595 · DOI · Paper page
- Parker, 1992, Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2, J. Immunol., 149, 3580, 10.4049/jimmunol.149.11.3580 · DOI · Paper page
- Hunt, 1992, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261, 10.1126/science.1546328 · DOI · Paper page
- Peakman, 2001, Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?, Immunology, 104, 361, 10.1046/j.1365-2567.2001.01335.x · DOI
- Voskens, 2009, Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome, Curr. Mol. Med., 9, 683, 10.2174/156652409788970724 · doi:10.2174/156652409788970724
- Cole, 2007, Human TCR-binding affinity is governed by MHC class restriction, J. Immunol., 178, 5727, 10.4049/jimmunol.178.9.5727 · DOI · Paper page
- Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat. Med., 4, 321, 10.1038/nm0398-321 · DOI · Paper page
- Houghton, 2007, Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes, Vaccine, 25, 5330, 10.1016/j.vaccine.2007.05.008 · doi:10.1016/j.vaccine.2007.05.008
- Speiser, 2008, Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen, Proc. Natl. Acad. Sci. USA, 105, 3849, 10.1073/pnas.0800080105 · DOI
- Skowera, 2008, CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope, J. Clin. Invest., 118, 3390
- Lissina, 2009, Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers, J. Immunol. Methods, 340, 11, 10.1016/j.jim.2008.09.014 · DOI
- Cole, 2009, Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor, J. Biol. Chem., 284, 27281, 10.1074/jbc.M109.022509 · DOI
- Wooldridge, 2007, Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region, Eur. J. Immunol., 37, 1323, 10.1002/eji.200636765 · DOI
- Garboczi, 1996, Structure of the complex between human T-cell receptor, viral peptide and HLA-A2, Nature, 384, 134, 10.1038/384134a0 · DOI · Paper page
- Boulter, 2003, Stable, soluble T-cell receptor molecules for crystallization and therapeutics, Protein Eng., 16, 707, 10.1093/protein/gzg087 · DOI · Paper page
- Wyer, 1999, T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics, Immunity, 10, 219, 10.1016/S1074-7613(00)80022-9 · DOI · Paper page
- Salter, 1986, Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid, EMBO J., 5, 943, 10.1002/j.1460-2075.1986.tb04307.x · DOI · Paper page
- Betts, 2003, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, J. Immunol. Methods, 281, 65, 10.1016/S0022-1759(03)00265-5 · DOI · Paper page
- Wooldridge, 2009, Tricks with tetramers: how to get the most from multimeric peptide-MHC, Immunology, 126, 147, 10.1111/j.1365-2567.2008.02848.x · DOI · Paper page
- Wooldridge, 2005, Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface, J. Biol. Chem., 280, 27491, 10.1074/jbc.M500555200 · DOI · Paper page
- Price, 2005, Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses, J. Exp. Med., 202, 1349, 10.1084/jem.20051357 · DOI · Paper page
- Lefranc, 2003, IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, Dev. Comp. Immunol., 27, 55, 10.1016/S0145-305X(02)00039-3 · DOI · Paper page
- Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat. Med., 10, 909, 10.1038/nm1100 · DOI · Paper page
- Bins, 2007, Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients, J. Immunother., 30, 234, 10.1097/01.cji.0000211333.06762.47 · DOI
- Meidenbauer, 2003, Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J. Immunol., 170, 2161, 10.4049/jimmunol.170.4.2161 · DOI
- Chen, 2005, Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination, Cancer Immun., 5, 5
- Clay, 1999, Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue, J. Immunol., 162, 1749, 10.4049/jimmunol.162.3.1749 · DOI
- Pass, 1998, Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay, Cancer J. Sci. Am., 4, 316
- Rubio, 2003, Ex vivo identification, isolation and analysis of tumor-cytolytic T cells, Nat. Med., 9, 1377, 10.1038/nm942 · DOI · Paper page
- Madden, 1993, The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2, Cell, 75, 693, 10.1016/0092-8674(93)90490-H · DOI · Paper page
- Guo, 1993, Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705, Proc. Natl. Acad. Sci. USA, 90, 8053, 10.1073/pnas.90.17.8053 · doi:10.1073/pnas.90.17.8053
- Speiser, 2002, In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells, Eur. J. Immunol., 32, 731, 10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.CO;2-H · DOI
- Varela-Rohena, 2008, Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor, Nat. Med., 14, 1390, 10.1038/nm.1779 · DOI · Paper page
- Borbulevych, 2007, Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition, J. Mol. Biol., 372, 1123, 10.1016/j.jmb.2007.07.025 · DOI
- Sliz, 2001, Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes, J. Immunol., 167, 3276, 10.4049/jimmunol.167.6.3276 · DOI
- Tynan, 2005, T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound peptide, Nat. Immunol., 6, 1114, 10.1038/ni1257 · doi:10.1038/ni1257
- Tynan, 2007, A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule, Nat. Immunol., 8, 268, 10.1038/ni1432 · DOI · Paper page
- Macdonald, 2009, T cell allorecognition via molecular mimicry, Immunity, 31, 897, 10.1016/j.immuni.2009.09.025 · DOI · Paper page
- Wieckowski, 2009, Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients, J. Immunol., 183, 5397, 10.4049/jimmunol.0901460 · DOI
- Vignard, 2005, Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J. Immunol., 175, 4797, 10.4049/jimmunol.175.7.4797 · DOI
- Serana, 2009, Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients, J. Transl. Med., 7, 21, 10.1186/1479-5876-7-21 · doi:10.1186/1479-5876-7-21
- Rudolph, 2006, How TCRs bind MHCs, peptides, and coreceptors, Annu. Rev. Immunol., 24, 419, 10.1146/annurev.immunol.23.021704.115658 · DOI · Paper page
- Borbulevych, 2005, Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design, J. Immunol., 174, 4812, 10.4049/jimmunol.174.8.4812 · doi:10.4049/jimmunol.174.8.4812
- Bowerman, 2009, Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity, Mol. Immunol., 46, 3000, 10.1016/j.molimm.2009.06.012 · DOI
- Finke, 2007, Lessons from randomized phase III studies with active cancer immunotherapies—outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC), Vaccine, 25, B97, 10.1016/j.vaccine.2007.06.067 · DOI
- Jones, 1996, Therapeutic vaccines for melanoma: progress and problems, Trends Biotechnol., 14, 349, 10.1016/0167-7799(96)10045-7 · doi:10.1016/0167-7799(96)10045-7
Cited by
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Why must T cells be cross-reactive?
Sewell, A. K. (2012) · Nature Reviews Immunology · doi:10.1038/nri3279 · Cited by 541
Self-citationAntigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes
Gee, M. H., Han, A., Lofgren, S. M., Beausang, J. F., Mendoza, J. L., Birnbaum, M. E., Bethune, M. T., Fischer, S., Yang, X., Gomez-Eerland, R., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.043 · Cited by 272
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Metadata
- Authors
- Cole, D. K., Edwards, E. S. J., Wynn, K. K., Clement, M., Miles, J. J., Ladell, K., Ekeruche, J., Gostick, E., Adams, K. J., Skowera, A., Peakman, M., Wooldridge, L., Price, D. A., & Sewell, A. K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-08
- Volume
- 185
- Issue
- 4
- Pages
- 2600-2610
- ISSN
- 0022-1767
- 1550-6606
- Cited by
- 115
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition. https://app.cochat.ai/papers/10.4049/jimmunol.1000629
- The paper
- Cole, D. K., Edwards, E. S. J., Wynn, K. K., Clement, M., Miles, J. J., Ladell, K., Ekeruche, J., Gostick, E., Adams, K. J., Skowera, A., Peakman, M., Wooldridge, L., Price, D. A., & Sewell, A. K. (2010). Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1000629
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.